Ruxolitinib for myelofibrosis therapy: Current context, pros and cons

Leukemia

Volumn 26, Issue 7, 2012, Pages 1449-1451

  Pardanani, A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; HEMOGLOBIN; HYDROXYUREA; INTERLEUKIN 6; INTERLEUKIN 8; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE INHIBITOR; PLACEBO; RUXOLITINIB; STAT PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL DISCOMFORT; ANEMIA; BONE PAIN; CHRONIC MYELOID LEUKEMIA; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DIZZINESS; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVITY; ENZYME INHIBITION; ERYTHROCYTE TRANSFUSION; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; HEADACHE; HIGH RISK PATIENT; HUMAN; LEUKOPENIA; MOLECULARLY TARGETED THERAPY; MYALGIA; MYELOFIBROSIS; NEUTROPENIA; NIGHT SWEAT; NUCLEAR MAGNETIC RESONANCE IMAGING; ORGAN SIZE; PERIPHERAL EDEMA; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PRURITUS; REVIEW; RISK BENEFIT ANALYSIS; SATIETY; SIGNAL TRANSDUCTION; SKIN BRUISING; SPLEEN; SPLENOMEGALY; SURVIVAL; THORAX PAIN; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOCYTOPENIA;

HUMANS; JANUS KINASES; PRIMARY MYELOFIBROSIS; PROGNOSIS; PYRAZOLES;

EID: 84863781835     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.21     Document Type: Review

References (15)

1. Verstovsek S, Mesa RA, Gotlib JR, Levy RS, Gupta V, DiPersio JF et al. Results of COMFORT-I, a randomized double-blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). J Clin Oncol 2011; 29 (Suppl; abstr 6500): 419s.
2. Harrison CL, Kiladjian J, Al-Ali HK, Gisslinger H, Waltzman RJ, Stalbovskaya V et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) or post-essential thrombocythemia-myelofibrosis (PET-MF). J Clin Oncol 2011; 29 (Suppl; abstr LBA6501): 419s.
3. Jakafi (Ruxolitinib) label http://www.accessdata.fda.gov/drugsatfda-docs/ label/2011/202192lbl.pdf.
4. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: results from COMFORT-I. Blood 53rd ASH Annu Meet 2011; 118 (abstr no. 278): 128-129.
5. Pardanani A, Vannucchi AM, Passamonti F, Cervantes F, Barbui T, Tefferi A. JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. Leukemia 2011; 25: 218-225.
6. Tefferi A, Barosi G, Mesa RA, Cervantes F, Deeg HJ, Reilly JT et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006; 108: 1497-1503.
7. Freireich EJ. The FDA-pharmaceutical industry complex. The ASCO Post 15 June 2011, Digital edition.
8. Caramazza D, Begna KH, Gangat N, Vaidya R, Siragusa S, Van Dyke DL et al. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. Leukemia 2011; 25: 82-88.
9. Tefferi A, Lasho TL, Jimma T, Finke CM, Gangat N, Vaidya R et al. One thousand patients with primary myelofibrosis: the mayo clinic experience. Mayo Clin Proc 2012; 87: 25-33.
10. Tefferi A, Gangat N, Vaidya R, Begna K, Hanson C, Van Dyke D et al. Predictors of greater than 80% two-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically-annotated cases. Blood 53rd ASH Annu Meet 2011; 118 (abstr no. 2806): 1210-1211.
11. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010; 363: 1117-1127.
12. Tefferi A, Litzow MR, Pardanani A. Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med 2011; 365: 1455-1457.
13. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010; 24: 1128-1138.
14. Lasho TL, Tefferi A, Finke C, Pardanani A. Clonal hierarchy and allelic mutation segregation in a myelofibrosis patient with two distinct LNK mutations. Leukemia 2011; 25: 1056-1058.
15. Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol 2011; 29: 1356-1363.